Medicines Australia says US drug pricing reforms are reshaping global launch decisions, with Australia at risk of slipping further down the queue for innovative medicines unless the PBS and HTA system are overhauled.
Medicines Australia says US drug pricing reforms are reshaping global launch decisions, with Australia at risk of slipping further down the queue for innovative medicines unless the PBS and HTA system are overhauled.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.